The November hemp change is usually discussed as a market story. Before it is a market story it is a paperwork story, and the paperwork is where most operators will first discover they have a problem.
The test itself changes
Section 781 of Public Law 119-37 replaces the hemp definition with one measuring:
“a total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid) of not more than 0.3 percent on a dry weight basis”
The previous federal test was delta-9 THC. The new one is total tetrahydrocannabinols with THCA named explicitly. Effective 365 days after the Act was signed on 12 November 2025.
Why this is a COA problem first
A certificate of analysis reports what was asked for. If your historical COAs report delta-9 THC against the 0.3 percent line, they are answering a question that stops being the legal question in November.
Three consequences follow.
Historical COAs do not transfer. A file showing compliance under the old test is not evidence of compliance under the new one. If a lot passed at 0.25 percent delta-9 while carrying substantial THCA, it fails the new test, and nothing about the material changed. Only the arithmetic did.
Method matters more than it did. Whether an analysis reports the acid form separately, and whether it applies a decarboxylation conversion factor when totalling, now determines the answer. Two labs can analyse the same sample and report different totals depending on how they handle THCA. That was a technical footnote. It is now the compliance line.
Your supplier’s paperwork inherits the same problem. If you buy inputs on the strength of a COA, you are relying on someone else’s test design. This is exactly the situation supplier certification frameworks exist to make legible, and it is why lab testing standards are worth interrogating before a deadline rather than after one.
The finished-product cap is a separate document
The 0.3 percent test applies to plant material and derivatives. Finished consumable products face a different exclusion: more than 0.4 milligrams combined total per container of total THC including THCA, plus any other cannabinoids with similar or similarly marketed effects as determined by HHS.
That is a per-container figure, so it depends on fill volume and packaging format, not only on concentration. Which means it cannot be answered by a COA on the input material at all. It requires a calculation at the finished-goods level, per SKU, per pack size.
Anyone whose quality file stops at input COAs has a gap here.
The combined-total trap
The cap is not THC-only. It reads “combined total… of total tetrahydrocannabinols (including tetrahydrocannabinolic acid); and any other cannabinoids that have similar effects (or are marketed to have similar effects)”.
Practically, that means a panel narrow enough to report only THC may not tell you whether a product complies. If a formulation carries minor cannabinoids that HHS later determines to have similar effects, they count toward the same 0.4mg. A broader cannabinoid panel is the conservative position, and it is cheaper than discovering the answer later.
What a sensible sequence looks like
Work out which SKUs are affected, at finished-goods level, per container size. Re-test representative lots on a method that reports total THC including THCA, and on a panel wide enough to cover minor cannabinoids. Ask every input supplier which test their COAs report against and whether they will issue total-THC documentation. Then, and only then, decide what needs reformulating.
Reformulation without the testing question settled is guesswork, and any change to a formula restarts your stability and storage evidence anyway.
The timing
The Senate released continuing resolution text on 2 August 2026 that would move most of these restrictions to 11 December 2026. As of 3 August 2026 it had not passed either chamber.
Testing turnaround, supplier response times and packaging lead times do not care which of those dates lands. If the delay passes, you gain four weeks on a workstream that takes longer than that.
About this article
Written 3 August 2026 and checked against the statute, the Federal Register and the published papers rather than against secondary coverage. Regulatory positions in this area are moving, so check the date before relying on it. Nothing here is legal, tax or medical advice.
